Document is current
Any future updates will be listed below
-
Authors
Peng, Lei
Hu, Yingxia
Mankowski, Madeleine C.
Ren, Ping
Chen, Rita E.
Wei, Jin
Zhao, Min
Li, Tongqing https://orcid.org/0000-0002-5272-4380
Tripler, Therese
Ye, Lupeng https://orcid.org/0000-0003-3901-6598
Chow, Ryan D. https://orcid.org/0000-0002-1872-6307
Fang, Zhenhao
Wu, Chunxiang https://orcid.org/0000-0002-8635-1578
Dong, Matthew B.
Cook, Matthew
Wang, Guilin
Clark, Paul
Nelson, Bryce
Klein, Daryl https://orcid.org/0000-0002-7188-0450
Sutton, Richard
Diamond, Michael S. https://orcid.org/0000-0002-8791-3165
Wilen, Craig B. https://orcid.org/0000-0003-2495-9403
Xiong, Yong https://orcid.org/0000-0001-9625-9313
Chen, Sidi https://orcid.org/0000-0002-3819-5005
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Center for Information Technology (R01 AI150334, R01 AI157155, R01 AI148467)
U.S. Department of Health & Human Services | NIH | Center for Information Technology
U.S. Department of Health & Human Services | NIH | Center for Information Technology
U.S. Department of Defense (W81XWH-21-1-0019)
- License Information
-
More Information
Article History
Received: 12 July 2021
Accepted: 4 March 2022
First Online: 28 March 2022
Competing interests
: A patent application has been filed by Yale University on the antibodies described here (inventors: S.C., L.P., and P.R.). Yale University has committed to rapidly executable nonexclusive royalty-free licenses to intellectual property rights for the purpose of making and distributing products to prevent, diagnose, and treat COVID-19 infection during the pandemic and for a short period thereafter. S.C. is a co-founder of EvolveImmune Tx and Cellinfinity Bio, unrelated to the study. M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, and Carnival Corporation, and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Moderna, and Emergent BioSolutions. The remaining authors declare no competing interests.
